Loading organizations...
Key people at Teva Pharmaceuticals.
Teva Pharmaceuticals develops and manufactures a broad portfolio of generic and specialty medicines, establishing itself as a global leader. The company leverages extensive research and development alongside a robust manufacturing and distribution network. Teva consistently expands its offerings, addressing diverse therapeutic areas and unmet medical needs globally.
The company began in Jerusalem in 1901 as Salomon, Levin and Elstein Ltd., founded by pharmacists. Initially, it distributed imported medicines throughout the region. Growth was driven by increasing demand for domestically produced pharmaceuticals. This led to its rebranding as Teva Pharmaceutical Industries Ltd. in 1976, a pivotal moment in its expansion.
Teva Pharmaceuticals primarily serves patients worldwide, providing access to a vast array of medications. Its long-term vision centers on improving human health by ensuring the availability of high-quality, affordable treatments. It continues to innovate across generic and specialty pharmaceutical domains, aiming to help individuals lead longer, healthier lives.
Key people at Teva Pharmaceuticals.
Teva Pharmaceutical Industries Ltd. is a global leader in generic and innovative biopharmaceutical medicines, ranking among the top 15-26 largest pharmaceutical companies worldwide.[1][2][3][4][6] Founded over 120 years ago, it develops, manufactures, and distributes affordable generics, specialty drugs, and biologics to patients in 57 markets, supported by 37,000 employees and a network focused on advancing healthcare through innovation and accessibility.[6] Teva serves healthcare providers, pharmacies, and patients by addressing critical needs in areas like neurology, respiratory health, oncology, and women's health, solving the problem of high drug costs via generics while pioneering treatments like multiple sclerosis therapies.[1][2][4]
Teva traces its roots to 1901 in Jerusalem, then part of the Ottoman Empire, when pharmacists Chaim Salomon, Moshe Levin, and Yitschak Elstein founded Salomon, Levin, and Elstein Ltd. (SLE), a small wholesale drug business distributing imported medicines via mule trains and camel caravans.[1][2][3][4][7][8] In the 1930s, amid growing demand for local production, immigrants established related firms like Assia and Zori; SLE spun off Assia, and by 1935, Günther Friedländer and Else Kober formalized Teva Middle East Pharmaceutical & Chemical Works Co. Ltd.[4] Key mergers in 1968 (Assia/Zori acquiring Teva) and 1976 (forming Teva Pharmaceutical Industries Ltd., Hebrew for "nature") under CEO Eli Hurvitz (1976-2002, Chairman until 2010) marked consolidation.[1][2][4] Early traction came from local manufacturing; pivotal global expansion began in the 1980s-2000s via acquisitions like Ikapharm (1980), Plantex (1980), Copley (1999), Sicor (2004), IVAX (2006), Barr (2008), and others, establishing dominance in generics across North America, Europe, and beyond.[1][2][4][5]
Teva rides the trend of healthcare democratization, where generics counter rising drug prices amid aging populations and chronic disease surges, making treatments accessible globally.[1][6] Timing aligns with post-patent cliffs for blockbusters and biosimilars' rise, amplified by market forces like regulatory approvals (e.g., Hatch-Waxman Act favoring generics) and demand in emerging markets.[2][4] It influences the ecosystem by pressuring originators on pricing, fostering competition, and investing in APIs/humanitarian supply, though facing antitrust scrutiny over alleged price-fixing.[4] In pharma's "tech" evolution, Teva leverages digital R&D and biologics to bridge traditional manufacturing with innovative therapies.
Teva's trajectory points to sustained generics dominance with growing biopharma focus, potentially via more biosimilars and CNS therapies amid patent expirations and AI-driven drug discovery.[6] Trends like personalized medicine, supply chain localization post-COVID, and inflation pressures will shape it, evolving its influence toward hybrid generic-innovator models. As a century-old pioneer, Teva remains pivotal in equitable healthcare, scaling from Jerusalem caravans to global leadership.
